Prescription Drug Patent Licensing Act

Summary

Prescription Drug Patent Licensing Act - Provides that whenever, upon complaint by a qualified applicant for a license under a drug patent, the Federal Trade Commission determines that such license application was not granted and that the price quoted to druggists by the patentee is more than 500 percent of the total cost of production, the Commission shall, after granting notice and the opportunity for a hearing, order the patentee (under penalty of patent cancellation by the Commissioner of Patents) to grant an unrestricted license to any qualified applicant to make, use, and sell such drug. Permits the Commission to delay the issuance of such order for up to five years to provide a fair return on the patentee's invested capital.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Introduced in House

  summary · EN · 19 January 1981

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.